Drug Profile
Research programme: metabotropic glutamate receptor 2/3 antagonists - BrainCells/Taisho Pharmaceutical
Alternative Names: BCI-1038; BCI-1208; BCI-1283; CNS programme - BrainCells/Taisho Pharmaceutical; Neurogenesis-promoting compoundsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Developer BrainCells
- Class
- Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - CNS disorders
Highest Development Phases
- No development reported CNS disorders; Mood disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mood disorders in USA
- 02 Mar 2012 A programme for metabotropic glutamate receptor 2/3 antagonists is available for licensing (\http://www.braincellsinc.com/\)